Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan. - Frega J; Somme L; Martin T; Petit T; Salvadori J; Bund C; Somme F (European journal of nuclear medicine and molecular imaging, 2026)